Tag - SVRA

Developments

Savara’s AeroVanc fails Phase 3 cystic fibrosis trial

Savara (NASDAQ:SVRA) reported that its Phase 3 AVAIL trial evaluating AeroVanc for the treatment of cystic fibrosis failed to meet its primary endpoint. The trial enrolled 55 cystic fibrosis patients with methicillin...

December 10, 2020

Developments

FDA rejects Savara’s Molgradex for autoimmune pulmonary alveolar proteinosis

Following a Type C FDA meeting, Savara (NASDAQ:SVRA) reported that the agency did not recommend it submit a biologics license application (BLA) for Molgradex for the treatment of autoimmune pulmonary alveolar...

October 2, 2019

Developments

Savara gets FDA fast track designation for autoimmune lung disease

The FDA granted Savara’s (NASDAQ:SVRA) Molgradex fast track designation for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP). aPAP occurs when the body’s immune system attacks granulocyte-macrophage...

May 6, 2019

Tag - SVRA

Savara’s AeroVanc fails Phase 3 cystic fibrosis trial

FDA rejects Savara’s Molgradex for autoimmune pulmonary alveolar proteinosis

Savara gets FDA fast track designation for autoimmune lung disease

General

More